首页> 外文期刊>The Journal of Nuclear Medicine >Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
【24h】

Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.

机译:重组人促甲状腺激素给药后,分化型甲状腺癌患者的血清甲状腺球蛋白浓度和(131)I全身扫描结果。

获取原文
获取原文并翻译 | 示例
           

摘要

The use of recombinant human thyroid-stimulating hormone (rhTSH) has recently become available as an alternative diagnostic tool to assess the persistence and recurrence of differentiated thyroid carcinoma (DTC) in patients on thyroid hormone-suppressive therapy (THST) after near-total or total thyroidectomy and ablative doses of (131)I. We report the results of rhTSH administration in patients who were monitored for DTC. METHODS: Thirty-three adult DTC patients (13 men, 20 women; mean age +/- SE, 45.6 +/- 2.31 y; age range, 21-65 y) underwent diagnostic follow-up after rhTSH administration at a dose of 0.9 mg once a day for 2 d. Whole-body scanning and serum thyroglobulin (Tg) measurement were performed after rhTSH administration. Patients were divided into 2 groups depending on serum Tg concentrations on THST: 29 patients had Tg concentrations of <2 ng/mL (group A) and 4 patients had Tg values of >2 ng/mL (group B). RESULTS: In group A, Tg values remained at <2 ng/mL in 25 patients and increased from 1.1 +/- 0.14 ng/mL to 22.0 +/- 5.75 ng/mL (mean +/- SE) in 4 patients after rhTSH administration. Whole-body scanning did not reveal any uptake of (131)I in the 25 patients without an increase in Tg, whereas (131)I uptake was evident in 2 of the 4 patients with a rise in Tg. In group B, Tg values increased in all 4 patients from 17.3 +/- 6.35 ng/mL to 55.3 +/- 12.75 ng/mL, and (131)I uptake was evident in 3 of the 4 patients. No major adverse effects were reported after rhTSH administration. CONCLUSION: Our results show that the measurement of serum Tg concentrations after rhTSH has a higher diagnostic value than whole-body scanning in detecting the persistence of thyroid tissue. Therefore, rhTSH should be administered in TSH-suppressed patients with basal serum Tg concentrations of <2 ng/mL because the increment in serum Tg concentrations may reveal the persistence of thyroid tissue in these patients.
机译:最近,重组人甲状腺刺激激素(rhTSH)的使用已成为一种可替代的诊断工具,用于评估接受全价或全剂量甲状腺激素抑制治疗(THST)的患者中分化型甲状腺癌(DTC)的持续性和复发性。甲状腺全切除术和消融剂量的(131)I。我们报告了在监测DTC的患者中rhTSH给药的结果。方法:rhTSH剂量为0.9的33例成人DTC患者(13例男性,20例女性;平均年龄+/- SE,45.6 +/- 2.31 y;年龄范围21-65岁)进行了诊断性随访。每天一次,持续2 d。 rhTSH给药后进行全身扫描和血清甲状腺球蛋白(Tg)测定。根据THST上的血清Tg浓度将患者分为2组:29位患者的Tg浓度<2 ng / mL(A组)和4位患者的Tg值> 2 ng / mL(B组)。结果:A组中,有25例患者的Tg值保持在<2 ng / mL,在rhTSH后4例患者的Tg值从1.1 +/- 0.14 ng / mL增加到22.0 +/- 5.75 ng / mL(平均+/- SE)行政。全身扫描未显示25例患者的(131)I摄取量没有增加,而Tg却没有升高,而4例患者中Tg升高的2例中有明显的(131)I摄取。在B组中,所有4例患者的Tg值均从17.3 +/- 6.35 ng / mL增加到55.3 +/- 12.75 ng / mL,并且在4例患者中有3例吸收了(131)I。 rhTSH给药后未见严重不良反应。结论:我们的结果表明,rhTSH后血清Tg浓度的测定对全身甲状腺组织的持久性具有比全身扫描更高的诊断价值。因此,应在TSH抑制的基础血清Tg浓度<2 ng / mL的患者中施用rhTSH,因为血清Tg浓度的增加可能表明这些患者的甲状腺组织持续存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号